BAW2881 | CAS#861875-60-7

MedKoo Cat#: 407228 | Name: BAW2881

Description:

WARNING: This product is for research use only, not for human or veterinary use.

BAW2881 is a potent and selective VEGFR inhibitor (vascular endothelial growth factor receptor tyrosine kinase inhibitor) with activity to inhibit chronic and acute skin inflammation. NVP-BAW2881 inhibited proliferation, migration, and tube formation by human umbilical vein endothelial cells and lymphatic endothelial cells in vitro. NVP-BAW2881 reduced the number of blood and lymphatic vessels and infiltrating leukocytes in the skin, and normalized the epidermal architecture. NVP-BAW2881 also displayed strong anti-inflammatory effects in models of acute inflammation; pretreatment with topical NVP-BAW2881 significantly inhibited VEGF-A-induced vascular permeability in the skin of pigs and mice.

Chemical Structure

BAW2881

CAS#861875-60-7

Theoretical Analysis

MedKoo Cat#: 407228

Name: BAW2881

CAS#: 861875-60-7

Chemical Formula: C22H15F3N4O2

Exact Mass: 424.1147

Molecular Weight: 424.38

Elemental Analysis: C, 62.26; H, 3.56; F, 13.43; N, 13.20; O, 7.54

Price and Availability

Size	Price	Availability
50mg	USD 450.00	2 Weeks
100mg	USD 750.00	2 Weeks
200mg	USD 1,250.00	2 Weeks
500mg	USD 2,650.00	2 Weeks
1g	USD 3,850.00	2 Weeks
2g	USD 6,450.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

BAW2881; BAW-2881; BAW 2881; NVP-BAW2881; NVP-BAW-2881; NVP-BAW 2881.

IUPAC/Chemical Name

6-((2-aminopyrimidin-4-yl)oxy)-N-(3-(trifluoromethyl)phenyl)-1-naphthamide

InChi Key

MLLQJNIKDWEEFT-UHFFFAOYSA-N

InChi Code

InChI=1S/C22H15F3N4O2/c23-22(24,25)14-4-2-5-15(12-14)28-20(30)18-6-1-3-13-11-16(7-8-17(13)18)31-19-9-10-27-21(26)29-19/h1-12H,(H,28,30)(H2,26,27,29)

SMILES Code

O=C(C1=C2C=CC(OC3=NC(N)=NC=C3)=CC2=CC=C1)NC4=CC=CC(C(F)(F)F)=C4

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

BAW2881 is a VEGFR2 inhibitor with an IC50 of 4 nM.

In vitro activity:

To determine whether NVP-BAW2881 had a blocking effect on VEGF-A-induced proliferation of endothelial cells, HUVECs were incubated in VEGF-A-containing medium in the presence or absence of NVP-BAW2881. Although VEGF-A promoted HUVEC cell proliferation (1.3-fold more cells, compared with control; P < 0.0001), the lowest concentration of NVP-BAW2881 tested (1 nmol/L) potently inhibited this response (Figure 1A). Similarly, when testing the effects of this compound on LEC proliferation, 1 nmol/L NVP-BAW2881 significantly reduced VEGF-A-induced proliferation, compared with controls (P < 0.001; Figure 1B). Since VEGF-C is thought to be main mediator of lymphangiogenesis in vivo, whether NVP-BAW2881 could also block VEGF-C-induced proliferation of LECs was evaluated. Although 1 μmol/L NVP-BAW2881 significantly reduced VEGF-C-induced LEC proliferation (P = 0.042, Figure 1C), lower concentrations of the compound did not have a significant effect. Furthermore, 10 nmol/L and 1 μmol/L concentrations of NVP-BAW2881 completely inhibited the migration of HUVECs and of LECs toward VEGF-A in in vitro transmigration assays (Figure 1, D and E). Reference: Am J Pathol. 2008 Jul;173(1):265-77. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2438303/

In vivo activity:

The in vivo effects of NVP-BAW2881 were evaluated in a transgenic mouse model of psoriasis. Psoriasis-like lesions were induced in the right ears of K14/VEGF-A mice by inducing a CHS response, and NVP-BAW2881 was administered, topically or orally, beginning 7 days later. A significant reduction in ear swelling was observed within 5 days in groups given oral doses (−21%, P = 0.003) and within 7 days in groups given topical applications (−25%, P = 0.006) of NVP-BAW2881 (Figure 3, A and B, respectively). At the defined study endpoint (14 days after treatment began; study day 21), ear swelling had decreased by 56% (P < 0.0001) in the oral treatment group, as compared with the control group. Similarly, topical treatment with NVP-BAW2881 reduced ear swelling by 43% (P = 0.0001) as compared with controls. Reference: Am J Pathol. 2008 Jul;173(1):265-77. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2438303/

	Solvent	mg/mL	mM
Solubility
	Ethanol	20.0	47.13
	DMF	30.0	70.69
	DMSO	50.0	117.82
	DMSO:PBS (pH 7.2) (1:2)	0.3	0.78

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 424.38 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Halin C, Fahrngruber H, Meingassner JG, Bold G, Littlewood-Evans A, Stuetz A, Detmar M. Inhibition of chronic and acute skin inflammation by treatment with a vascular endothelial growth factor receptor tyrosine kinase inhibitor. Am J Pathol. 2008 Jul;173(1):265-77. doi: 10.2353/ajpath.2008.071074. Epub 2008 Jun 5. PMID: 18535184; PMCID: PMC2438303.

In vitro protocol:

In vivo protocol:

1: Halin C, Fahrngruber H, Meingassner JG, Bold G, Littlewood-Evans A, Stuetz A, Detmar M. Inhibition of chronic and acute skin inflammation by treatment with a vascular endothelial growth factor receptor tyrosine kinase inhibitor. Am J Pathol. 2008 Jul;173(1):265-77. doi: 10.2353/ajpath.2008.071074. Epub 2008 Jun 5. PubMed PMID: 18535184; PubMed Central PMCID: PMC2438303. 2. Liu Y, Li Y, Hou R, Shu Z. Knockdown GREM1 suppresses cell growth, angiogenesis, and epithelial-mesenchymal transition in colon cancer. J Cell Biochem. 2019 Apr;120(4):5583-5596. doi: 10.1002/jcb.27842. Epub 2018 Nov 13. PMID: 30426548.